Clinical Trials Browser

Phase 2 × Recruiting × niraparib × Clear all

NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06180356 2026-04-22

ANALLISA

Phase 2 Recruiting

Ovarian Neoplasms

NCT05183984 2026-04-13

NIRVANA-1

Phase 2 Recruiting

Ovarian Neoplasms

NCT05718323 2026-02-06

RAISE

Phase 2 Recruiting

SCLC,Extensive Stage

NCT05700721 2026-02-05

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Phase 2 Recruiting

Brain Neoplasms

NCT05526989 2025-12-04

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Phase 2 Recruiting

Penile Neoplasms

NCT04641247 2025-09-29

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Phase 2 Recruiting

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT06747845 2025-09-16

ParpVax2

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT05990192 2025-04-22

SOPRANO

Phase 2 Recruiting

Ovarian Neoplasms

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2 Recruiting

Rare Tumor

NCT04812366 2024-12-16

GUNS

Phase 2 Recruiting

Prostatic Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

Phase 2 Recruiting

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT04716686 2024-01-05

Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

Phase 2 Recruiting

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT05961124 2023-11-22

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms

NCT06141265 2023-11-21

BRAND

Phase 2 Recruiting

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

NCT04681469 2022-08-04

PRIME

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Phase 2 Recruiting

Fallopian Tube Neoplasms